One dose of the antiviral baloxavir marboxil lowers the chance of transmitting the influenza virus to family members by about ...

Xofluza (baloxavir marboxil) met its primary endpoint in the CENTERSTONE trial, reducing the odds of untreated household ...

One dose of the antiviral baloxavir marboxil lowers the chance of transmitting the influenza virus to family members by about ...

A single dose of the antiviral baloxavir marboxil (Xofluza) led to a lower incidence of influenza virus transmission to ...

Baloxavir marboxil (baloxavir) rapidly reduces influenza virus shedding, which suggests that it may reduce transmission. Studies of treatment with neuraminidase inhibitors have not shown ...

Detailed results from the CENTERSTONE trial show treatment with Xofluza reduced the odds of transmission, or spread of the ...

A landmark study published in The New England Journal of Medicine [link to the publication] reveals that a single oral dose of baloxavir marboxil ...

Baloxavir marboxil (baloxavir) is an oral antiviral medication that is FDA-approved for early treatment (within 48 hours after symptom onset) of uncomplicated influenza and for postexposure ...

For further information on how we select topics for development, please see our page about topic selection ...